川芎嗪注射液治疗copd急性加重期临床的研究

《川芎嗪注射液治疗copd急性加重期临床的研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、目录中文摘要···················································1英文摘要···················································3引言····················································6正文···················································71研究对象与方法·······················

2、······················71.1研究对象来源与分组········································71.2病例选择标准········································81.2.1COPD急性加重期诊断标准································81.2.2纳入标准··············································101.2.3排除标准···········

3、···································101.2.4剔除标准··············································101.2.5症状体征分级标准······································101.2.6疗效标准··············································112研究方法·············································

4、·····122.1治疗方法················································122.1.1对照组···············································122.1.2治疗组···············································122.2观测方法················································122.2.1临床症状体征指标的观测···

5、·····························122.2.2客观指标的观测········································122.2.3安全性指标···········································132.3统计学方法··············································143结果与分析················································143.

6、1治疗组与对照组临床疗效比较······························143.2治疗组与对照组单项症状体征治疗后积分差比较··············143.3治疗组与对照组肺动脉压的比较····························153.4治疗组与对照组CO的比较·································153.5治疗组与对照组ET-1的比较·······························163.6ET-1、CO与动脉血气指标的相关性

7、分析······················163.7对肝、肾功能的观察·······································173.8大、小便常规的检查·······································174讨论······················································174.1西医对COPD的认识与肺动脉压增高的过程···················174.2中医对COPD的认识与肺动脉压关

8、系的研究···················184.3川芎嗪注射液的药理分析··································234.4内源性CO···············································244.5内源性ET-1·············································265存在的问题与展望························